Bárbara Adamo

7.9k total citations · 2 hit papers
99 papers, 3.7k citations indexed

About

Bárbara Adamo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Bárbara Adamo has authored 99 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 53 papers in Pulmonary and Respiratory Medicine and 46 papers in Cancer Research. Recurrent topics in Bárbara Adamo's work include Advanced Breast Cancer Therapies (37 papers), Breast Cancer Treatment Studies (36 papers) and HER2/EGFR in Cancer Research (29 papers). Bárbara Adamo is often cited by papers focused on Advanced Breast Cancer Therapies (37 papers), Breast Cancer Treatment Studies (36 papers) and HER2/EGFR in Cancer Research (29 papers). Bárbara Adamo collaborates with scholars based in Spain, United States and Italy. Bárbara Adamo's co-authors include Aleix Prat, Charles M. Perou, Patricia Galván, Montserrat Muñoz-Mateu, Lisa A. Carey, Carey K. Anders, Aranzazu Fernández-Martínez, Estela Pineda, Margarita Viladot and Ana Arance and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Bárbara Adamo

90 papers receiving 3.6k citations

Hit Papers

Clinical implications of the intrinsic molecular subtypes... 2015 2026 2018 2022 2015 2020 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinical implications of the intrinsic molecular subtypes of breast cancer
    2015 751 citations Aleix Prat, Estela Pineda et al. The Breast profile →
  2. Frequency and spectrum of PIK3CA somatic mutations in breast cancer
    2020 227 citations Olga Martínez‐Sáez, Núria Chic et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bárbara Adamo Spain 25 1.8k 1.7k 1.4k 1.0k 308 99 3.7k
Mónica Arnedos France 25 1.6k 0.9× 1.4k 0.8× 1.2k 0.9× 1.0k 1.0× 293 1.0× 90 3.1k
Kazunori Tsukuda Japan 34 1.5k 0.9× 2.1k 1.2× 1.0k 0.7× 1.5k 1.5× 274 0.9× 121 3.7k
Florence Lerebours France 29 1.4k 0.8× 915 0.5× 1.2k 0.9× 692 0.7× 304 1.0× 97 2.6k
Dorthe Grabau Sweden 28 1.5k 0.8× 1.3k 0.8× 1.6k 1.1× 510 0.5× 380 1.2× 57 3.0k
Gaia Schiavon United Kingdom 28 2.5k 1.4× 1.5k 0.9× 1.9k 1.3× 1.7k 1.7× 644 2.1× 105 4.6k
Alberto Bottini Italy 32 1.6k 0.9× 1.1k 0.6× 1.5k 1.0× 510 0.5× 368 1.2× 117 3.1k
Ewan K.A. Millar Australia 33 1.3k 0.7× 1.8k 1.0× 1.1k 0.8× 525 0.5× 450 1.5× 80 3.4k
Alessia Ciarrocchi Italy 33 1.2k 0.7× 2.4k 1.4× 1.0k 0.7× 639 0.6× 272 0.9× 115 4.0k
Mohammed A. Aleskandarany United Kingdom 36 1.6k 0.9× 1.7k 1.0× 1.5k 1.0× 510 0.5× 382 1.2× 81 3.4k
Adrian M. Jubb United Kingdom 32 1.6k 0.9× 2.5k 1.4× 1.0k 0.7× 630 0.6× 367 1.2× 50 4.0k

Countries citing papers authored by Bárbara Adamo

Since Specialization
Citations

This map shows the geographic impact of Bárbara Adamo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bárbara Adamo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bárbara Adamo more than expected).

Fields of papers citing papers by Bárbara Adamo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bárbara Adamo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bárbara Adamo. The network helps show where Bárbara Adamo may publish in the future.

Co-authorship network of co-authors of Bárbara Adamo

This figure shows the co-authorship network connecting the top 25 collaborators of Bárbara Adamo. A scholar is included among the top collaborators of Bárbara Adamo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bárbara Adamo. Bárbara Adamo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rodríguez, A., Linda M. Polfus, Brittany Bychkovsky, et al.. (2025). Low Allele Frequency Variants Identified on Germline Multi-Gene Panel Testing for Cancer Predisposition Can Suggest the Presence of Constitutional Mosaicism. Clinical Cancer Research. 31(13). 2814–2823.
2.
Sanfeliu, Esther, Elia Seguí, Raquel Gómez Bravo, et al.. (2024). Abstract PO2-01-13: Clinico-Pathological and Molecular Characterization of Early Hormone Receptor-Positive Breast Cancer in Young Women. Cancer Research. 84(9_Supplement). PO2–1. 1 indexed citations
3.
Schettini, Francesco, Tomás Pascual, Fara Brasó‐Maristany, et al.. (2023). 55P Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive (HR+)/HER2-low vs HER2 0 breast cancer (BC). ESMO Open. 8(1). 101279–101279. 1 indexed citations
4.
Schettini, Francesco, Olga Martínez‐Sáez, Claudette Falato, et al.. (2023). Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis. ESMO Open. 8(3). 101214–101214. 8 indexed citations
5.
Martínez‐Sáez, Olga, Fara Brasó‐Maristany, Mercedes Marín‐Aguilera, et al.. (2023). 8P First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer. ESMO Open. 8(1). 101232–101232.
6.
Moreno, L., Roxana Reyes, Daniel Martı́nez, et al.. (2022). 138P Prevalence and characteristics of lung cancer in families harboring pathogenic germline variants in cancer predisposing genes. Annals of Oncology. 33. S95–S95. 2 indexed citations
7.
8.
Prat, Aleix, Yi‐Hsuan Tsai, Tomás Pascual, et al.. (2020). A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer. Clinical Cancer Research. 26(23). 6141–6148. 5 indexed citations
9.
Martínez‐Sáez, Olga, Tomás Pascual, Fara Brasó‐Maristany, et al.. (2020). 5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i). Annals of Oncology. 31. S17–S17.
10.
González‐Farré, Blanca, Paolo Nucíforo, Javier Cortés, et al.. (2020). 15P The CelTIL score as an early predictor of anti-tumour response following neoadjuvant therapy (NAT): A SOLTI biomarker analysis. Annals of Oncology. 31. S22–S22.
11.
Adamo, Bárbara, Lorena Moreno, Lydia Gaba, et al.. (2019). Multi-gene panel testing at the hereditary breast and ovarian cancer (HBOC) unit of the Hospital Clinic of Barcelona. Annals of Oncology. 30. iii42–iii43.
12.
Griguolo, Gaia, Fara Brasó‐Maristany, Tomás Pascual, et al.. (2019). ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC). Annals of Oncology. 30. iii7–iii7. 4 indexed citations
13.
Adamo, Bárbara, José Alejandro Pérez Fidalgo, Eva Ciruelos, et al.. (2017). VENTANA (SOLTI-1501): Antiproliferative effect of the addition of oral metronomic vinorelbine to endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial. Annals of Oncology. 28. v66–v66. 1 indexed citations
14.
Prat, Aleix, Patricia Galván, Begoña Jiménez, et al.. (2015). Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. Clinical Cancer Research. 22(3). 560–566. 64 indexed citations
15.
Karginova, Olga, Marni B. Siegel, Amanda E.D. Van Swearingen, et al.. (2015). Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA -Mutated and BRCA –Wild-Type Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 14(4). 920–930. 53 indexed citations
16.
Prat, Aleix, Huihui Fan, Aranzazu Fernández-Martínez, et al.. (2015). Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Medicine. 13(1). 303–303. 112 indexed citations
17.
Prat, Aleix, Estela Pineda, Bárbara Adamo, et al.. (2015). Clinical implications of the intrinsic molecular subtypes of breast cancer. The Breast. 24. S26–S35. 751 indexed citations breakdown →
18.
Soria, J.C., Filippo de Braud, Rastilav Bahleda, et al.. (2014). Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Annals of Oncology. 25(11). 2244–2251. 147 indexed citations
19.
Malin, Dmitry, Elena Strekalova, Vladimír Petrovič, et al.. (2013). αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain. Clinical Cancer Research. 20(1). 56–67. 81 indexed citations
20.
Prat, Aleix, Bárbara Adamo, Maggie C.U. Cheang, et al.. (2013). Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer. The Oncologist. 18(2). 123–133. 403 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mónica Arnedos Breakdown of academic impact, for papers by Kazunori Tsukuda Breakdown of academic impact, for papers by Florence Lerebours Breakdown of academic impact, for papers by Dorthe Grabau Breakdown of academic impact, for papers by Gaia Schiavon Breakdown of academic impact, for papers by Alberto Bottini Breakdown of academic impact, for papers by Ewan K.A. Millar Breakdown of academic impact, for papers by Alessia Ciarrocchi Breakdown of academic impact, for papers by Mohammed A. Aleskandarany Breakdown of academic impact, for papers by Adrian M. Jubb
Rankless by CCL
2026